Abstract
CIRS-G scores and serum creatinine levels demonstrated potential predictability for prognostic value in forecasting mortality among long-living male patients. Moreover, a potential association between CIRS-G score and intestinal microbiome was observed. These results underscore the intricate impact of comorbidities and polypharmacy on intestinal microbiome composition and clinical consequences. Clinically, the CIRS-G score could serve as a valuable tool for identifying high-risk elderly patients who may benefit from closer monitoring and individualized interventions. However, the small sample size, monocentric design, and potential confounders limit generalizability. These findings support further validation in larger cohorts.
Introduction
As the global population ages, "multimorbidity" (the presence of multiple chronic diseases) and "polypharmacy" (the use of multiple medications) have become defining characteristics of geriatric care. While it is well-established that aging and medication use alter the gut microbiome, the relationship between these microbial shifts and actual survival outcomes in the "oldest old" remains poorly understood.
This study, published in Frontiers in Cellular and Infection Microbiology, investigates whether clinical parameters and gut microbial profiles can serve as reliable biomarkers to predict 18-month mortality in elderly male patients (mean age 94) receiving multi-drug therapy.
Clinical Predictors of Mortality
The researchers followed 33 patients admitted to a geriatric ward in Wuhan, China. Using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) to quantify the burden across 14 organ systems, the study found that the CIRS-G score was a remarkably accurate predictor of mortality, with an Area Under the Curve (AUC) of 0.967.
Higher CIRS-G scores (Hazard Ratio: 1.323) and elevated serum creatinine levels (HR: 1.007) were identified as the primary independent risk factors for death. Interestingly, the total number of medications taken did not significantly correlate with mortality, suggesting that the severity of underlying disease (as captured by CIRS-G) is a more critical driver of clinical outcomes than polypharmacy alone.
Gut Microbiome Composition and Survival
The study utilized 16S rRNA gene sequencing to profile the intestinal microbiome from stool samples collected at admission. While no significant differences were found in overall alpha or beta diversity between survivors and non-survivors, distinct compositional differences emerged at various taxonomic levels.
At the phylum level, Firmicutes and Proteobacteria were dominant across both groups. However, more granular analysis at the genus level revealed specific microbial signatures associated with survival:
- Survivors (No-death group): Enriched with Erysipelatoclostridium and Lactobacillus (0.075 vs 0.011). The authors suggest these may play a role in producing beneficial short-chain fatty acids like butyrate.
- Non-survivors (Death group): Showed a higher relative abundance of Prevotella (0.088 vs 0.002) and Sutterella. Sutterella was positively correlated with higher CIRS-G scores and creatinine levels, indicating a potential link to pro-inflammatory states and disease severity.
Conclusion and Limitations
The findings suggest that integrating clinical tools like the CIRS-G score with microbiome profiling could enhance prognostic accuracy in geriatric medicine. However, the study's small sample size (n=33), male-only cohort, and monocentric design limit the generalizability of these results. Future longitudinal studies with larger, more diverse populations are necessary to validate these microbial biomarkers and explore their potential in guiding personalized interventions for high-risk elderly patients.
Summary updated